SELECT-1
Synergistic Real-world Study and Evidence-based Medicine Evaluation of Elemene Combined With Tyrosine Kinase Inhibitors（TKIs）in the Treatment of Advanced Non-small Cell Lung Cancer（NSCLC）：Retrospective Study
Sponsor study identifier
observational
878
1 country
19
Study Start
August 28, 2020
Actual (reported)Primary Completion
April 30, 2023
Actual (reported)Study Completion
March 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This is a nationwide, multicenter and retrospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 18, 2020
Actual (reported)May 21, 2020
Actual (reported)August 28, 2020
Actual (reported)April 30, 2023
Actual (reported)March 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
OS
OS was defined as the interval from the date of the administration of the first-dose TKIs to date of death from any cause, or the date of last known follow-up alive.
June 2021
PFS
June 2021
ORR
June 2021
DCR
June 2021
KPS score
June 2021
ECOG score
June 2021
This is a real-world study, we just record the patient's medication who used Elemene Injectable Emulsion and/or Elemene Oral Emulsion plus TKIs. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.
This is a real-world study, we just record the patient's medication who used TKIs only. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.
Patients with advanced non-small cell lung cancer and EGFR mutation who visited the research centers from January 2014 to December 2017 and received TKIs therapy with or without Elemene.
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
Panjin Central Hospital
Panjin, Liaoning, China
Shenyang Tenth People's Hospital
Shenyang, Liaoning, 110000, China
The Second People's Hospital of Yangcheng County
Jincheng, Shanxi, China
Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Hangzhou Cancer Hospital
Hangzhou, Zhejiang, China
Tongde Hospital of Zhejiang Province
Hangzhou, Zhejiang, China
Ziping Wang, PhD
Peking University Cancer Hospital & Institute
878 participants (actual enrollment reported by the registry).
First Submitted
May 18, 2020
First Posted
May 21, 2020
Study Start
August 28, 2020
Actual (reported)Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial
Contact the study team to confirm eligibility.
Zhejiang Hospital
Hangzhou, Zhejiang, China
Zhejiang Xiaoshan Hospital
Hangzhou, Zhejiang, China
Hangzhouwan Hospital
Ningbo, Zhejiang, China
Dongfang Hospital Beijing University of Chinese Medicine
Beijing, 100078, China
Beijing Cancer Hospital
Beijing, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
Cancer Hospital of Huanxing Chaoyang District Beijing
Beijing, China
Chongqing University Cancer Hospital
Chongqing, China
Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Shanghai, China
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Shanghai, China
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
Tianjin, China
Tianjin Medical University General Hospital
Tianjin, China
Primary Completion
April 30, 2023
Actual (reported)Study Completion
March 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 27, 2023
Record last verified: 2023-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: